spebrutinib
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01351935)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Irreversible inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1- Mol. weight
- 423.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301625 ↗
- ChEMBLCHEMBL3301600 ↗
Also known as
- avl-292
- avl-292
- avl-292
- cc-292
- cc-292
- cc-292
- cc-292
- n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
- spebrutinib
- spebrutinib
- spebrutinib
- spebrutinib besylate
- spebrutinib besylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02433457 | Phase 1 | May 1, 2014 | Celgene |
| NCT02031419 | Phase 1 | Dec 18, 2013 | Celgene |
| NCT01975610 | Phase 2 | Oct 1, 2013 | Celgene |
| NCT01766583 | Phase 1 | Feb 1, 2013 | Celgene, The Lymphoma Academic Research Organisation, University of Lyon, University of Toulouse |
| NCT01732861 | Phase 1 | Dec 28, 2012 | Celgene |
| NCT01744626 | Phase 1 | Dec 1, 2012 | Celgene |
| NCT01692184 | Phase 1 | Aug 1, 2012 | Celgene |
| NCT01351935 | Phase 1 | Jul 1, 2011 | Celgene, The Leukemia and Lymphoma Society |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 8 | 7 | 2 | 2011 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2011 |
| The Lymphoma Academic Research Organisation | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1